Company: GHRS
Filing Date: 2025-02-05
Form Type: 424B5
Source: 0001140361-25-003183
Chunk: 14

Company: GH Research PLC
Filing Date: 2025-02-05
Form: 424B5
Chunk 14
---
 purchase additional shares), representing an immediate increase of $1.67 per ordinary share. If you invest in our ordinary shares in this offering, you will experience immediate dilution of $9.69 per ordinary share, which is the difference between the public offering price and our as adjusted net tangible book value per ordinary share.

If the underwriters’ option to purchase additional shares is exercised in full, the as adjusted net tangible book value per ordinary share after this offering would increase to $5.51. This represents an immediate increase in net tangible book value of $1.87 per ordinary share to existing shareholders and an immediate dilution of $9.49 per ordinary share to investors in this offering.

To the extent that any outstanding options under our share-based compensation plans are exercised, new equity awards are issued under our share-based compensation plans or we issue additional ordinary shares, or securities exercisable or convertible for ordinary shares, in the future, there will be further dilution to investors participating in this offering.

<div align='center'>S-12</div>

#### TABLE OF CONTENTS

### USE OF PROCEEDS
We estimate that our net proceeds from the issuance and sale by us of ordinary shares in this offering will be approximately $139.8 million (or $160.8 million if the underwriters’ option to purchase additional shares is exercised in full), after deducting underwriting discounts and commissions and estimated offering expenses payable by us.

We intend to use the net proceeds from this offering to strategically invest in research, clinical and technical development of current and/or additional product candidates, working capital, capital expenditures and general corporate purposes.

Our expected use of the net proceeds from this offering represents our current intentions based on our present plans and business condition, which could change as our plans and business conditions evolve. The amounts and timing of our actual use of the net proceeds from this offering will vary depending on numerous factors. As a result, we cannot predict with certainty all of the particular uses for any net proceeds to be received or the amounts that we will actually spend on the uses set forth above. Our Board of Directors and our management retain broad discretion in the application of the net proceeds from this offering.

<div align='center'>S-13</div>

TABLE OF CONTENTS

TAXATION The following summary contains a description of material U.S. federal income and Irish tax consequences of the acquisition, ownership and disposition of our ordinary shares. This summary should not be considered a comprehensive description of all the tax considerations that may be relevant to the decision to acquire